MCID: ADL096
MIFTS: 50

Adult Hepatocellular Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Rare diseases

Aliases & Classifications for Adult Hepatocellular Carcinoma

MalaCards integrated aliases for Adult Hepatocellular Carcinoma:

Name: Adult Hepatocellular Carcinoma 12 60
Adult Primary Hepatocellular Carcinoma 12 74
Adult Hepatoma 12
Nci:c7956 12
Adult Hcc 60

Characteristics:

Orphanet epidemiological data:

60
adult hepatocellular carcinoma
Inheritance: Not applicable;

Classifications:

Orphanet: 60  
Rare hepatic diseases


External Ids:

Disease Ontology 12 DOID:0070328
ICD10 via Orphanet 35 C22.0
Orphanet 60 ORPHA210159
UMLS 74 C0279607

Summaries for Adult Hepatocellular Carcinoma

Disease Ontology : 12 A hepatocellular carcinoma is characterized by hepatic mass, abdominal pain and, in advanced stages, jaundice, cachexia and liver failure and often develops in the setting of chronic necro-inflammation.

MalaCards based summary : Adult Hepatocellular Carcinoma, also known as adult primary hepatocellular carcinoma, is related to hepatocellular carcinoma and pediatric hepatocellular carcinoma, and has symptoms including fever, abdominal pain and icterus. An important gene associated with Adult Hepatocellular Carcinoma is CASP8 (Caspase 8), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Doxorubicin and Iodine have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and bone, and related phenotypes are cardiovascular system and growth/size/body region

Related Diseases for Adult Hepatocellular Carcinoma

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Adult Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Related Disease Score Top Affiliating Genes
1 hepatocellular carcinoma 28.5 AXIN1 CASP8 CTNNB1 PDGFRL PIK3CA TP53
2 pediatric hepatocellular carcinoma 11.3
3 macrodactyly 10.2 PIK3CA TSC1
4 rare adenocarcinoma of the breast 10.2 PIK3CA TP53
5 malignant spiradenoma 10.2 PIK3CA TP53
6 uterine corpus serous adenocarcinoma 10.2 PIK3CA TP53
7 breast squamous cell carcinoma 10.2 PIK3CA TP53
8 uterine body mixed cancer 10.2 PIK3CA TP53
9 anal squamous cell carcinoma 10.2 PIK3CA TP53
10 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.2 PIK3CA TP53
11 uterine corpus cancer 10.2 PIK3CA TP53
12 prostate transitional cell carcinoma 10.1 CTNNB1 PIK3CA
13 kidney angiomyolipoma 10.1 TSC1 TSC2
14 angiomyolipoma 10.1 TSC1 TSC2
15 subependymal glioma 10.1 TSC1 TSC2
16 benign ependymoma 10.1 TSC1 TSC2
17 hemimegalencephaly 10.1 CTNNB1 PIK3CA
18 lissencephaly with cerebellar hypoplasia 10.1 TSC1 TSC2
19 maxillary cancer 10.1 EGF TP53
20 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.1 TSC1 TSC2
21 ovary adenocarcinoma 10.1 PIK3CA TP53
22 corneal dystrophy, fleck 10.1 TSC1 TSC2
23 subependymal giant cell astrocytoma 10.1 TSC1 TSC2
24 tuberous sclerosis 1 10.0 TSC1 TSC2
25 oral cavity cancer 10.0 CASP8 PIK3CA TP53
26 central nervous system benign neoplasm 10.0 TP53 TSC2
27 female reproductive endometrioid cancer 10.0 CTNNB1 TP53
28 skin squamous cell carcinoma 10.0 PIK3CA TP53
29 penile cancer 10.0 PIK3CA TP53
30 epstein-barr virus-associated gastric carcinoma 10.0 CTNNB1 PIK3CA
31 tongue disease 10.0 CTNNB1 TP53
32 tuberous sclerosis 9.9 PIK3CA TSC1 TSC2
33 acinar cell carcinoma 9.9 CTNNB1 TP53
34 gastrointestinal system benign neoplasm 9.9 CTNNB1 TP53
35 lymphoma, non-hodgkin, familial 9.9 CASP8 PIK3CA TP53
36 polycystic kidney disease 1 with or without polycystic liver disease 9.9 EGF TSC1 TSC2
37 cystic kidney disease 9.9 EGF TSC1 TSC2
38 glioblastoma multiforme 9.9 EGF PIK3CA TP53
39 autosomal dominant polycystic kidney disease 9.9 EGF TSC1 TSC2
40 ovarian clear cell carcinoma 9.9 PIK3CA TP53
41 intestinal benign neoplasm 9.9 CTNNB1 TP53
42 uterine anomalies 9.9 CTNNB1 PIK3CA TP53
43 carcinosarcoma 9.9 CTNNB1 PIK3CA TP53
44 focal cortical dysplasia, type ii 9.9 TP53 TSC1 TSC2
45 respiratory system cancer 9.9 CTNNB1 PIK3CA TP53
46 uterine carcinosarcoma 9.9 CTNNB1 PIK3CA TP53
47 intestinal disease 9.9 CTNNB1 PIK3CA TP53
48 esophageal basaloid squamous cell carcinoma 9.9 AXIN1 CTNNB1 TP53
49 gastrointestinal system cancer 9.9 CTNNB1 PIK3CA TP53
50 embryonal sarcoma 9.9 AXIN1 CTNNB1 TP53

Graphical network of the top 20 diseases related to Adult Hepatocellular Carcinoma:



Diseases related to Adult Hepatocellular Carcinoma

Symptoms & Phenotypes for Adult Hepatocellular Carcinoma

UMLS symptoms related to Adult Hepatocellular Carcinoma:


fever, abdominal pain, icterus, malaise

MGI Mouse Phenotypes related to Adult Hepatocellular Carcinoma:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 AXIN1 CASP8 CTNNB1 PIK3CA TP53 TSC1
2 growth/size/body region MP:0005378 10.06 AXIN1 CASP8 CTNNB1 EGF PIK3CA TP53
3 cellular MP:0005384 10.05 AXIN1 CASP8 CTNNB1 PIK3CA TP53 TSC1
4 embryo MP:0005380 10.04 AXIN1 CASP8 CTNNB1 PIK3CA TP53 TSC1
5 endocrine/exocrine gland MP:0005379 10.02 CASP8 CTNNB1 EGF PIK3CA TP53 TSC1
6 integument MP:0010771 9.98 CASP8 CTNNB1 EGF PIK3CA TP53 TSC1
7 liver/biliary system MP:0005370 9.8 CASP8 CTNNB1 TP53 TSC1 TSC2
8 neoplasm MP:0002006 9.8 CASP8 CTNNB1 PIK3CA TP53 TSC1 TSC2
9 nervous system MP:0003631 9.8 AXIN1 CASP8 CTNNB1 PIK3CA TP53 TSC1
10 muscle MP:0005369 9.77 CASP8 CTNNB1 PIK3CA TP53 TSC1
11 renal/urinary system MP:0005367 9.63 AXIN1 CASP8 CTNNB1 TP53 TSC1 TSC2
12 reproductive system MP:0005389 9.5 AXIN1 CTNNB1 EGF PIK3CA TP53 TSC1
13 respiratory system MP:0005388 9.02 AXIN1 CASP8 CTNNB1 TP53 TSC1

Drugs & Therapeutics for Adult Hepatocellular Carcinoma

Drugs for Adult Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Iodine Approved, Investigational Phase 3 7553-56-2 807
3 Ethiodized oil Approved, Investigational Phase 3 8008-53-5
4
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 284461-73-0 216239 406563
5
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
6
Sunitinib Approved, Investigational Phase 2, Phase 3 557795-19-4, 341031-54-7 5329102
7
Sodium Citrate Approved, Investigational Phase 3 68-04-2
8
Tamoxifen Approved Phase 3 10540-29-1 2733526
9
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
10
Pravastatin Approved Phase 3 81093-37-0 54687
11
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 143 6006
12
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
14
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
15 Nolatrexed Investigational Phase 3 147149-76-6
16 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
17 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
18 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
20 Nutrients Phase 3,Phase 2
21 Anti-Infective Agents Phase 3,Phase 2,Phase 1
22 Anti-Infective Agents, Local Phase 3
23 Trace Elements Phase 3,Phase 2
24 cadexomer iodine Phase 3
25 Micronutrients Phase 3,Phase 2
26 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
27 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
28 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
29 Hormone Antagonists Phase 3,Phase 2
30 Antineoplastic Agents, Hormonal Phase 3,Phase 2
31 Hormones Phase 3,Phase 2
32 Estrogens Phase 3,Phase 2
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
34 Antimetabolites Phase 3,Phase 2,Phase 1
35 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
36 Estrogen Receptor Antagonists Phase 3
37 Selective Estrogen Receptor Modulators Phase 3
38 Citrate Phase 3
39 Estrogen Receptor Modulators Phase 3
40 Bone Density Conservation Agents Phase 3,Phase 2
41 Estrogen Antagonists Phase 3
42 Central Nervous System Stimulants Phase 3,Not Applicable
43 Contraceptives, Oral Phase 3
44 Appetite Stimulants Phase 3
45 Contraceptive Agents Phase 3
46
Megestrol Phase 3 3562-63-8 3080587 19090
47 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
48 Hypolipidemic Agents Phase 3,Phase 2
49 Lipid Regulating Agents Phase 3,Phase 2
50 Anticholesteremic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 144)
# Name Status NCT ID Phase Drugs
1 Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) Unknown status NCT00079027 Phase 3 doxorubicin hydrochloride
2 Radioactive Iodine in Treating Patients Who Have Undergone Surgery for Liver Cancer Unknown status NCT00027768 Phase 3
3 Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Unknown status NCT01324076 Phase 3 doxorubicin-eluting beads;sorafenib tosylate
4 A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC Completed NCT01829035 Phase 3
5 Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer Completed NCT01164202 Phase 2, Phase 3 sunitinib malate;Placebo
6 Tamoxifen in Treating Patients With Primary Liver Cancer Completed NCT00003424 Phase 3 tamoxifen citrate
7 Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Completed NCT00041275 Phase 3 megestrol acetate
8 Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis Completed NCT01075555 Phase 3 pravastatin sodium;sorafenib tosylate
9 Iodine I 131 Ethiodized Oil in Preventing Recurrent Cancer in Patients Who Have Undergone Treatment for Liver Cancer Completed NCT00870558 Phase 3 ethiodized oil
10 Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery Completed NCT00109954 Phase 3 cisplatin
11 Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer Completed NCT00012324 Phase 3 doxorubicin hydrochloride;nolatrexed dihydrochloride
12 Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer Recruiting NCT01730937 Phase 3 sorafenib tosylate
13 Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Active, not recruiting NCT01015833 Phase 3 Doxorubicin Hydrochloride;Sorafenib Tosylate
14 Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma Terminated NCT01405573 Phase 3 sorafenib
15 Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma Unknown status NCT02418988 Phase 2 TACE plus rAd-p53 artery injection;TACE
16 An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects Unknown status NCT02409524 Phase 2
17 Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery Unknown status NCT01182272 Phase 2 sorafenib tosylate
18 Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis Unknown status NCT00132041 Phase 2
19 Sorafenib Tosylate With or Without Gemcitabine Hydrochloride and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer Unknown status NCT00941967 Phase 2 gemcitabine hydrochloride;oxaliplatin;sorafenib tosylate
20 Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery Unknown status NCT00471484 Phase 2 doxorubicin hydrochloride;fluorouracil;oxaliplatin
21 Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer Unknown status NCT00276705 Phase 2 cisplatin;cyclophosphamide;doxorubicin hydrochloride;thalidomide
22 Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer Unknown status NCT00553683 Phase 1, Phase 2 cyclophosphamide;poly ICLC
23 Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
24 Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Completed NCT02024087 Phase 1, Phase 2 Dalantercept plus sorafenib
25 Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma Completed NCT01777594 Phase 2 G-202
26 Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma Completed NCT01488487 Phase 2 Everolimus;Pasireotide
27 PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection Completed NCT01395030 Phase 2 18F-fluoromethylcholine
28 A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma Completed NCT02234986 Phase 2 ENMD-2076
29 Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence Completed NCT02447679 Phase 2 thalidomine;tegafur-uracil
30 Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer Completed NCT01005199 Phase 2 everolimus;sorafenib tosylate
31 Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer Completed NCT00238394 Phase 2 cediranib maleate
32 Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer Completed NCT00055692 Phase 2
33 Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery Completed NCT00006016 Phase 2 thalidomide;doxorubicin hydrochloride
34 Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery Completed NCT00949182 Phase 2 sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C
35 Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer Completed NCT00881751 Phase 2 erlotinib hydrochloride;sorafenib tosylate
36 Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Completed NCT00875615 Phase 2 Carboplatin;Cisplatin;Sorafenib
37 Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery Completed NCT00128596 Phase 2 arsenic trioxide
38 Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer Completed NCT00087282 Phase 2 alvocidib;irinotecan hydrochloride
39 IMC-A12 in Treating Patients With Advanced Liver Cancer Completed NCT00639509 Phase 2
40 Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer Completed NCT00604721 Phase 2 selumetinib
41 Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer Completed NCT00365391 Phase 2 erlotinib hydrochloride
42 Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Completed NCT00321594 Phase 1, Phase 2 belinostat
43 Doxorubicin and Bortezomib in Treating Patients With Liver Cancer Completed NCT00083226 Phase 2 doxorubicin;bortezomib
44 Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) Completed NCT00077441 Phase 2 bortezomib
45 Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) Completed NCT00071994 Phase 2 gefitinib
46 Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Completed NCT00777894 Phase 1, Phase 2
47 Oxaliplatin in Treating Patients With Liver Cancer Completed NCT00052364 Phase 2 oxaliplatin
48 Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Completed NCT00004248 Phase 2 doxorubicin hydrochloride
49 Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma Completed NCT00057980 Phase 1, Phase 2 celecoxib;epirubicin hydrochloride
50 T900607 in Treating Patients With Unresectable Liver Cancer Completed NCT00054262 Phase 2 T900607

Search NIH Clinical Center for Adult Hepatocellular Carcinoma

Genetic Tests for Adult Hepatocellular Carcinoma

Anatomical Context for Adult Hepatocellular Carcinoma

MalaCards organs/tissues related to Adult Hepatocellular Carcinoma:

42
Liver, Kidney, Bone, Breast, Colon, Endothelial, Prostate

Publications for Adult Hepatocellular Carcinoma

Articles related to Adult Hepatocellular Carcinoma:

# Title Authors Year
1
Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: A propensity-matching cohort study. ( 29602016 )
2018
2
Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma. ( 26990031 )
2016
3
Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: comparison study of childhood and adult hepatocellular carcinoma. ( 10847487 )
2000

Variations for Adult Hepatocellular Carcinoma

Cosmic variations for Adult Hepatocellular Carcinoma:

9 (show top 50) (show all 3365)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1626018 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 0
2 COSM1615665 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 0
3 COSM1602238 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 0
4 COSM6951673 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 0
5 COSM1616325 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 0
6 COSM3707827 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 0
7 COSM3707828 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 0
8 COSM1623051 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 0
9 COSM1612127 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 0
10 COSM1618451 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581L 4:145885684-145885684 0
11 COSM1611545 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 0
12 COSM1612685 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47V 19:52002156-52002156 0
13 COSM1612018 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 0
14 COSM1618219 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 0
15 COSM1624399 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 0
16 COSM1609798 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 0
17 COSM1605856 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 0
18 COSM1602404 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 0
19 COSM1607880 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221A 14:67807621-67807621 0
20 COSM3661787 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 0
21 COSM1270878 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 0
22 COSM1612900 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 0
23 COSM3663890 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 0
24 COSM6969923 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 0
25 COSM3717069 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 0
26 COSM6219678 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 0
27 COSM1613453 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 0
28 COSM3717124 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 0
29 COSM1608898 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 0
30 COSM3705381 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 0
31 COSM1601838 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 0
32 COSM1610770 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 0
33 COSM1601260 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 0
34 COSM1624206 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2136A>G p.T712T 8:80518852-80518852 0
35 COSM1624207 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2311A>G p.I771V 8:80519295-80519295 0
36 COSM1616586 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 0
37 COSM1624117 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1568A>G p.N523S 8:63187582-63187582 0
38 COSM1603361 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 0
39 COSM1617254 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167N 3:183722100-183722100 0
40 COSM3663693 XPO7 liver,NS,carcinoma,hepatocellular carcinoma c.806A>G p.Y269C 8:21977812-21977812 0
41 COSM1609152 XPO6 liver,NS,carcinoma,hepatocellular carcinoma c.882C>T p.G294G 16:28156289-28156289 0
42 COSM6957749 XPO1 liver,NS,carcinoma,hepatocellular carcinoma c.301+1G>C p.? 2:61522610-61522610 0
43 COSM1624082 XKR4 liver,NS,carcinoma,hepatocellular carcinoma c.1076A>G p.D359G 8:55523350-55523350 0
44 COSM1613650 XIRP2 liver,NS,carcinoma,hepatocellular carcinoma c.9350G>C p.R3117P 2:167250742-167250742 0
45 COSM3660541 XIRP1 liver,NS,carcinoma,hepatocellular carcinoma c.142C>A p.Q48K 3:39189304-39189304 0
46 COSM1625463 XIAP liver,NS,carcinoma,hepatocellular carcinoma c.493G>T p.A165S 23:123886155-123886155 0
47 COSM3663909 WWP1 liver,NS,carcinoma,hepatocellular carcinoma c.210-2A>G p.? 8:86381503-86381503 0
48 COSM1625309 WWC3 liver,NS,carcinoma,hepatocellular carcinoma c.1121C>A p.S374Y 23:10117180-10117180 0
49 COSM1621161 WTAP liver,NS,carcinoma,hepatocellular carcinoma c.283C>T p.Q95* 6:159748200-159748200 0
50 COSM6909096 WT1 liver,NS,carcinoma,hepatocellular carcinoma c.1019T>G p.L340* 11:32396283-32396283 0

Expression for Adult Hepatocellular Carcinoma

Search GEO for disease gene expression data for Adult Hepatocellular Carcinoma.

Pathways for Adult Hepatocellular Carcinoma

Pathways related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 AXIN1 CASP8 CTNNB1 EGF PIK3CA TP53
2
Show member pathways
13.66 AXIN1 CASP8 CTNNB1 EGF TP53 TSC1
3
Show member pathways
13.12 AXIN1 CASP8 CTNNB1 EGF TSC1 TSC2
4
Show member pathways
12.82 CASP8 CTNNB1 PIK3CA TP53 TSC2
5
Show member pathways
12.77 EGF PIK3CA TSC1 TSC2
6
Show member pathways
12.77 CASP8 CTNNB1 PIK3CA TP53 TSC1 TSC2
7
Show member pathways
12.68 AXIN1 CASP8 PIK3CA TP53
8
Show member pathways
12.62 AXIN1 CTNNB1 EGF PIK3CA TP53
9
Show member pathways
12.6 EGF PIK3CA TP53 TSC2
10
Show member pathways
12.59 AXIN1 CTNNB1 EGF PIK3CA TP53 TSC2
11
Show member pathways
12.56 EGF PIK3CA TP53 TSC1 TSC2
12
Show member pathways
12.54 CASP8 CTNNB1 PIK3CA TSC2
13 12.52 AXIN1 CASP8 CTNNB1 EGF PIK3CA TP53
14
Show member pathways
12.39 AXIN1 CASP8 CTNNB1 EGF PIK3CA TP53
15
Show member pathways
12.34 AXIN1 CTNNB1 TP53
16
Show member pathways
12.33 PIK3CA TP53 TSC1 TSC2
17
Show member pathways
12.33 CASP8 CTNNB1 PIK3CA TP53
18
Show member pathways
12.32 CASP8 CTNNB1 EGF PIK3CA TP53
19 12.31 AXIN1 CTNNB1 TP53
20
Show member pathways
12.3 PIK3CA TSC1 TSC2
21
Show member pathways
12.3 EGF PIK3CA TSC1 TSC2
22
Show member pathways
12.28 PIK3CA TP53 TSC1 TSC2
23
Show member pathways
12.27 CASP8 TP53 TSC2
24
Show member pathways
12.27 AXIN1 PIK3CA TP53 TSC1 TSC2
25 12.25 CTNNB1 PIK3CA TP53
26 12.19 CTNNB1 PIK3CA TP53
27 12.19 CASP8 PIK3CA TP53
28
Show member pathways
12.11 PIK3CA TP53 TSC1 TSC2
29 12.08 CTNNB1 EGF TP53
30
Show member pathways
12.06 CTNNB1 EGF PIK3CA
31 12.05 PIK3CA TP53 TSC1 TSC2
32 12.03 PIK3CA TP53 TSC1 TSC2
33
Show member pathways
12.02 CASP8 PIK3CA TSC2
34 12 AXIN1 CASP8 CTNNB1
35
Show member pathways
12 PIK3CA TP53 TSC1 TSC2
36 11.99 CTNNB1 PIK3CA TP53
37 11.98 AXIN1 CTNNB1 PIK3CA
38
Show member pathways
11.98 CTNNB1 EGF PIK3CA TSC2
39 11.95 AXIN1 CTNNB1 TP53
40 11.95 PIK3CA TSC1 TSC2
41
Show member pathways
11.92 CASP8 PIK3CA TP53
42 11.84 CTNNB1 PIK3CA TP53 TSC2
43 11.82 AXIN1 CTNNB1 PIK3CA TP53
44 11.78 PIK3CA TSC1 TSC2
45 11.74 TP53 TSC1 TSC2
46 11.74 CASP8 CTNNB1 TP53 TSC1 TSC2
47 11.67 CASP8 PIK3CA TP53
48 11.6 AXIN1 CTNNB1 TP53
49 11.38 TP53 TSC1 TSC2
50
Show member pathways
11.36 EGF PIK3CA

GO Terms for Adult Hepatocellular Carcinoma

Cellular components related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.62 AXIN1 CTNNB1 TSC1 TSC2
2 protein-containing complex GO:0032991 9.56 CASP8 CTNNB1 TP53 TSC1
3 lamellipodium GO:0030027 9.33 CTNNB1 PIK3CA TSC1
4 beta-catenin destruction complex GO:0030877 8.96 AXIN1 CTNNB1
5 TSC1-TSC2 complex GO:0033596 8.62 TSC1 TSC2

Biological processes related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.81 AXIN1 CTNNB1 EGF TP53
2 regulation of apoptotic process GO:0042981 9.77 CASP8 CTNNB1 TP53
3 viral process GO:0016032 9.62 CASP8 CTNNB1 TP53 TSC2
4 protein kinase B signaling GO:0043491 9.58 PIK3CA TSC2
5 negative regulation of TOR signaling GO:0032007 9.58 TSC1 TSC2
6 negative regulation of insulin receptor signaling pathway GO:0046627 9.57 TSC1 TSC2
7 positive regulation of macroautophagy GO:0016239 9.56 TSC1 TSC2
8 negative regulation of cell proliferation GO:0008285 9.56 CTNNB1 TP53 TSC1 TSC2
9 response to antibiotic GO:0046677 9.55 CASP8 TP53
10 ERBB2 signaling pathway GO:0038128 9.54 EGF PIK3CA
11 positive regulation of peptidyl-threonine phosphorylation GO:0010800 9.52 AXIN1 EGF
12 vasculature development GO:0001944 9.49 CTNNB1 PIK3CA
13 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.48 CASP8 TP53
14 beta-catenin destruction complex disassembly GO:1904886 9.46 AXIN1 CTNNB1
15 positive regulation of ubiquitin-dependent protein catabolic process GO:2000060 9.43 AXIN1 EGF
16 negative regulation of macroautophagy GO:0016242 9.4 PIK3CA TSC1
17 negative regulation of oxidative stress-induced neuron death GO:1903204 9.37 CTNNB1 TSC1
18 anoikis GO:0043276 9.16 PIK3CA TSC2
19 regulation of calcium ion import GO:0090279 8.96 CTNNB1 EGF
20 regulation of protein localization to cell surface GO:2000008 8.62 CTNNB1 EGF

Molecular functions related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Hsp90 protein binding GO:0051879 9.16 TSC1 TSC2
2 disordered domain specific binding GO:0097718 8.96 CTNNB1 TP53
3 I-SMAD binding GO:0070411 8.62 AXIN1 CTNNB1

Sources for Adult Hepatocellular Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....